(Sharecast News) - Crism Therapeutics used its annual general meeting on Tuesday to highlight progress on its ChemoSeed drug delivery platform as it advances towards key clinical milestones.
Non-executive chair Dr Nermeen Varawalla told shareholders the company had submitted its clinical trial authorisation application to the UK's Medicines and Healthcare products...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE